Next Article in Journal
Effect of YC-1102 on the Improvement of Obesity in High-Fat Diet-Induced Obese Mice
Next Article in Special Issue
Extracellular Vesicles Isolated from Equine Adipose-Derived Stromal Stem Cells (ASCs) Mitigate Tunicamycin-Induced ER Stress in Equine Corneal Stromal Stem Cells (CSSCs)
Previous Article in Journal
A Narrative Review of Preclinical In Vitro Studies Investigating microRNAs in Myocarditis
Previous Article in Special Issue
Inflammation and Starvation Affect Housekeeping Gene Stability in Adipose Mesenchymal Stromal Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CIMB
Volume 46
Issue 2
10.3390/cimb46020092
cimb-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Association between Donor Age and Osteogenic Potential of Human Adipose Stem Cells in Bone Tissue Engineering

by
Md Abdus Sattar
,
Lara F. Lingens
,
Vincent G. J. Guillaume
,
Rebekka Goetzl
,
Justus P. Beier
and
Tim Ruhl
*
Department of Plastic Surgery, Hand Surgery—Burn Center, University Hospital, Rheinisch-Westfälische Technische Hochschule Aachen, 52074 Aachen, Germany
*
Author to whom correspondence should be addressed.
Curr. Issues Mol. Biol. 2024, 46(2), 1424-1436; https://doi.org/10.3390/cimb46020092
Submission received: 23 December 2023 / Revised: 26 January 2024 / Accepted: 2 February 2024 / Published: 6 February 2024
(This article belongs to the Special Issue Molecular Research in Stem Cells)
Browse Figures
Review Reports Versions Notes

Abstract

:
Adipose stem cells (ASCs) have multilineage differentiation capacity and hold great potential for regenerative medicine. Compared to bone marrow-derived mesenchymal stem cells (bmMSCs), ASCs are easier to isolate from abundant sources with significantly higher yields. It is generally accepted that bmMSCs show age-related changes in their proliferation and differentiation potentials, whereas this aspect is still controversial in the case of ASCs. In this review, we evaluated the existing data on the effect of donor age on the osteogenic potential of human ASCs. Overall, a poor agreement has been achieved because of inconsistent findings in the previous studies. Finally, we attempted to delineate the possible reasons behind the lack of agreements reported in the literature. ASCs represent a heterogeneous cell population, and the osteogenic potential of ASCs can be influenced by donor-related factors such as age, but also gender, lifestyle, and the underlying health and metabolic state of donors. Furthermore, future studies should consider experimental factors in in vitro conditions, including passaging, cryopreservation, culture conditions, variations in differentiation protocols, and readout methods.

1. Introduction

Human bone tissue can regenerate spontaneously after fracture or injury through a bone remodeling process consisting of four phases (Figure 1). Within the first five days after injury, the fracture hematoma is formed accompanied by local inflammation, resulting in the activation and migration of immune cells, including macrophages, monocytes, and lymphocytes [1,2]. Next, the regenerating cells of the connective tissue, including mesenchymal stem cells (MSCs), are recruited to the site of injury, and the fibrocartilaginous fracture callus is formed by the rapid proliferation and differentiation of MSCs into chondroblasts, osteoblasts, and fibroblasts. The differentiation of MSCs is induced by several mediators of cell differentiation such as bone morphogenic proteins (BMPs). The expression and localization of BMPs (e.g., BMP-2 and BMP-4) during early fracture healing have been reported in the literature [3,4]. The vascular endothelial growth factors (VEGFs) secreted by immune cells promote angiogenesis through the formation of new blood vessels. The third phase involves the endochondral ossification of the cartilage where soft cartilage is replaced by a hard bone callus. VEGF-mediated vascularization continues deeper into the callus and facilitates further migration of MSCs and the supply of oxygen and nutrition. Finally, the newly formed bone callus is continuously remodeled by the resorption of osteoclasts and the formation of osteoblasts [1,5,6].
This spontaneous bone healing is a multilateral process that is regulated by various intrinsic and extrinsic factors and can be disrupted by various causes at various time points, resulting in a failure to heal successfully [7]. Modern surgical techniques augment natural as well as impaired healing by grafting autologous, allogenic, or prosthetic materials to the recipient site [8]. However, the transfer of autologous material is limited by the availability of appropriate tissue, and it holds the risk of donor-site morbidity, unpredictable graft absorption, infections, and structural failure.
To address these issues, bone repair through osteogenic tissue engineering could combine suitable progenitor cells with appropriate scaffolds and growth factors [2]. Autologous stem cell transplantation includes cell isolation and the subsequent in vitro expansion, eventually followed by the transplantation into the defect site. However, this strategy is challenged by the availability of suitable stem cell populations with sufficient intrinsic potential for osteogenic differentiation. Admittedly, age-related changes in stem cell characteristics are an important criterion that should be taken into account when considering autologous stem cell therapy for bone tissue regeneration and/or artificial bone tissue engineering. Although the clinical applicability of MSCs spans all age groups, elderly people are the primary beneficiaries of stem cell-based regenerative medicine because degenerative bone diseases, and delayed or impaired fracture healing are more prevalent in the elderly population. In addition, the risk for bone deformation and fractures per se increases with age, while it is associated with a decreased ability for tissue regeneration and repair. Age-associated microenvironmental changes, such as metabolic alteration, hormonal disturbance, and immunological disorders, might also affect the stem cell niche and, thus, impair the regenerative potential of the MSCs [9]. Moreover, aging induces profound changes in various molecular, genetic, and epigenetic processes, resulting in alterations to the proliferation and differentiation potential of MSCs. Ultimately, this leads to disrupted tissue homeostasis and impaired repair abilities [10]. Therefore, it is not only important to find a suitable autologous cell population with the potential to regenerate bone tissue but also crucial to choose an MSC type that is less affected by age. The most promising candidates are adipose stem cells (ASCs) and MSCs derived from bone marrow (bmMSCs), members of the MSC family, which share unique features for osteogenic differentiation [11,12].
bmMSCs have multilineage differentiation potential, and their use in regenerative medicine is not restricted by ethical issues. However, as discussed in previous reviews [13,14,15,16,17], several disadvantages restrict the use of bmMSCs in bone tissue engineering. For example, bmMSC isolation procedures can be associated with donor-site morbidities such as pain, infection, hematomas, seromas, nerve injuries, arterial injuries, and fractures [18]. In addition, aging negatively impacts bmMSC harvests because the cell yield declines with age [19]. Moreover, a negative age effect is observed in both the proliferation as well as osteogenic differentiation potential of bmMSCs [19,20,21,22]. Additionally, bmMSCs isolated from elderly donors exhibit increased senescence properties and ROS-induced oxidative damage [20,21,22]. It has been postulated that the bmMSCs from elderly donors favor adipogenic differentiation instead of osteogenic differentiation, a process termed the “adipogenic switch” [13,14,17].
Compared to bmMSCs, ASCs are abundantly available, can be isolated through a minimally invasive liposuction procedure, and yield a higher number of cells [23]. Meyer et al. obtained nearly 2–3 million cells with stem cell properties from a mere 10 mL sample of lipoaspirate [24]. ASCs hold the capacity to differentiate into adipocytes, chondrocytes, osteoblasts, skeletal muscle cells, and tenocytes, in vitro [25]. The regenerative potential of ASCs and ASC-derived secretomes have been substantiated in numerous studies, and when combined with 3D scaffolds and microfluidic systems, ASCs support bone as well as soft tissue repair and regenerative processes [25]. For example, a case report involving 52 males diagnosed with stage I avascular necrosis (AVN) of the femoral head and treated with core decompression and injection of ASCs from abdominal liposuction reported the healing of the bone lesion after three months [26].
A clear and widely accepted definition of ASCs is yet to be determined, particularly concerning the unique expression of cell surface markers [27]. In 2006, the International Society for Cell and Gene Therapy (ISCT) proposed three main criteria of MSCs, namely their ability to adhere to the plastic surface; being positive for CD73, CD90, CD105, and negative for CD45, CD34, CD14, CD19, and HLA-DR; and their ability to differentiate into adipocytes, osteoblasts, and chondrocytes. In 2013, the International Federation for Adipose Therapeutics and Science (IFATS) and ISCT defined phenotypic markers specific to the ASC population [28]. According to the joint statement, the stromal vascular fraction (SVF) obtained by the collagenase digestion of adipose tissue should be characterized by CD31−, CD45−, CD235a−, and CD34+. The cultured ASCs should retain the markers of MSCs (being positive for CD44, CD73, CD90, and CD105) and can be distinguished from bmMSCs by CD36+ and CD106−.
The mechanism through which ASCs promote bone fracture healing is not clearly understood. It was suggested that the bone repair process by ASCs is primarily mediated by their paracrine activity, i.e., by the release of soluble factors such as growth factors, cytokines, chemokines, and extracellular vesicles. Among others, the ASC secretome includes immunomodulatory cytokines (e.g., interleukins and TNFa), and proangiogenic factors (e.g., VEGF and HGF). As shown in Figure 1, multiple factors contribute to fracture healing, including immune cells, growth factors, stem cells, chondroblasts, osteoblasts, and osteoclasts. The ASC secretome supports bone healing by recruiting immune cells, supporting osteogenic differentiation of progenitor cells, and promoting the generation of new blood vessels (angiogenesis) at the site of injury [2]. Localized differentiation mediators such as BMP-4 can induce the differentiation of ASCs into osteoblasts [29], which may further accelerate the bone repair process. Although the ASC-mediated acceleration of the bone repair process can be achieved by both differentiated and undifferentiated ASCs [30], it was reported that osteogenically induced ASCs perform better in fracture healing than uninduced ASCs [31].
Despite the great potential of ASCs in artificial bone tissue engineering, age-related changes in ASC functions remain elusive. Understanding the age-associated changes in ASC osteogenesis is of high importance when determining the optimal therapeutical applications of ASCs.
Researchers explored the effect of aging on the regenerative potential of ASCs in many studies. However, inconsistent results have been reported in the literature. Dufrane (2017) reviewed the impact of age on ASC isolation, the risk of oncogenicity, and bone tissue engineering and concluded that adipose cell properties are not dependent on donor age [32]. A systematic review from 2017 analyzed the results from 41 in vitro, in vivo, and clinical studies and found a decreased proliferation and differentiation potential of ASCs with increasing age [33]. In the present review, we aimed to update the current understanding of the impact of age on the osteogenic potential of human ASCs. We excluded studies that isolated ASCs from non-human sources because studying human aging in short-lived animal models remains controversial [34]. Furthermore, ASCs derived from non-human species are not suitable for transplantation into humans due to immunological disparities. To the best of our knowledge, this is the first review that focuses exclusively on the effect of age on the osteogenic potential of ASCs derived from humans.
A literature search was performed using Google Scholar and PubMed databases, and a total of 65 papers published between 2005 and 2021 were identified. Then, 50 papers were excluded, and 15 papers based on primary research involving human (h)ASCs met the criteria and were included in the final review (Figure 2). Among the 15 reviewed studies, 8 studies recruited both males and females, 6 studies included females only, and the gender of the donors was unspecified in 1 study. As summarized in Table 1 and reviewed in the following section, little consensus has been reached in the literature regarding the effect of donor age on the osteogenic potential of hASCs.

2. Review of Previous Studies

Among the 15 original studies included in this review, 7 studies reported no significant influence of age on the osteogenic differentiation capacity of hASCs. For example, Chen et al. evaluated the effect of age on the osteogenic potential of hASCs from 14 young patients with hip fracture (36.4 ± 11.8 years) and 8 elderly patients (71.4 ± 3.6 years) with osteoporosis. The results from their study indicate that age is not an influential factor in terms of matrix mineralization and the calcification of hASCs. However, the mRNA expression of osteocalcin and ALP genes decreased in the hASCs of elderly donors [37]. Wu et al. investigated the effect of age on the osteogenic potential of hASCs isolated from infant (<1 year), adult (20–54 years), and elderly (>55 years) donors. Although RUNX2 and osteocalcin mRNA expression and matrix mineralization were higher in infant ASCs, these parameters were overall comparable to those from adult and elderly donors [38]. A complex relationship between donor age and the osteogenic potential of hASCs from female donors was revealed in a study by Zhu et al. Age-associated decline in hASC osteogenesis was not significant in the study population (20–58 years). However, a significant decline in osteogenesis, in terms of decreased matrix calcification in the von Kossa staining, was observed when female donors entered their 40s, which suggests that these changes may be associated with estrogen loss during the transition of women from pre- to perimenopause [35]. To overcome the high interindividual variability between various donors, Bodle et al. generated ASC “superlots”, i.e., pooled donor cell populations derived from four to five age-clustered premenopausal (24–36 years), perimenopausal (48–55 years), and postmenopausal (60–81 years) female donors. With this superlot approach, the authors revealed that despite high donor-to-donor variability, young hASCs are primed to the adipogenic lineage, whereas old hASCs (60–81 years) preferentially differentiate osteogenically [40]. A report from Kawagishi-Hotta and colleagues included hASCs from a large number of donors (n = 260) aged 5–97 years old. The authors concluded that age negatively impacts adipogenic differentiation but not chondrogenic and osteogenic differentiation, measured by Oil Red O staining, sulfated glycosaminoglycan content, and Alizarin Red S staining, respectively. The principle component analysis (PCA) for ASC characteristics revealed that the proliferation and multilineage differentiation varied in each individual, particularly in females at an age of >60 years. Another study investigated the differentiation potential of hASCs derived from nine young (<36 years) and nine elderly (>54 years) donors. After osteogenic induction for up to four weeks, no significant differences were observed between hASCs of young and elderly donors in terms of matrix mineralization, evaluated by the OsteoImage™ Mineralization Assay, and the expression levels of osteogenic genes (RUNX2 and CEBPA), measured by quantitative PCR [47].
In contrast, eight studies found a diminishing effect of donor age on the osteogenic function of hASCs. For instance, Alt et al. presented a correlation between age-related changes in the quality of stem cells and differentiation capabilities using hASCs from young (<20), middle-aged (30–40), and elderly (>50) healthy donors. They observed an age-dependent downregulation of miRNAs (mir-27B and let-7G), which regulate the cell cycle, apoptosis, and inhibition of the multilineage potential of hASCs [10]. Similarly, Choudhery et al. studied the influence of age on the in vitro differentiation of hASCs from young (<30), adult (35–50 years), and aged (>60 years) individuals. In this study, the cells from aged donors displayed higher cellular senescence (confirmed by increased SA-β-gal staining), which correlated with a lowered level of cell mineralization in von Kossa staining compared to their young counterparts [39]. The association between donor age and the differentiation potential of human orbital adipose-derived stem cells (OASCs) was investigated by Ye et al. [41]. OASCs were isolated from the lower eyelid of young (20–38 years) and adult (50–67 years) female individuals who underwent routine blepharoplasty. OASCs from older donors displayed increased expression levels of senescence-related genes (p21 and p53) as well as decreased calcium deposition detected in the Alizarin Red assay [41]. Similarly, in another study, human eyelid ASCs showed decreased Alizarin Red staining for matrix calcification and a decreased expression of the osteoblastic gene OPN [46].
Marędziak and colleagues isolated hASCs from the subcutaneous fat of 28 healthy donors divided into four age groups: >20 years, >50 years, >60 years, and >70 years. They confirmed that the age group classified as younger (20–49 years) displayed a higher level of matrix calcification in Alizarin Red assay and an increased expression of osteogenic factors (osteocalcin, BMP-2, and osteopontin) in RT-PCR and ELISA, compared to age group >50 years [42,49]. A similar observation was reported by Liu et al. in the following year on hASCs from adipose tissue of children (6–12 years), adults (22–27 years), and elderly individuals (60–73 years) [43]. They observed an age-associated increased cellular senescence manifested by an increase in SA-β-gal-positive cells, as well as a decline in osteogenic potential marked by the downregulation of osteogenic genes (RUNX2, BMP-2, osteocalcin, and osteopontin) in RT-PCR and decreased matrix calcification in Alizarin Red staining in hASCs from elderly donors [43].
Since the regenerative potential of hASCs to support local tissue repair is predominantly attributed to their paracrine activity, a recent study illustrated that the age-altered secretory patterns of hASCs lead to the reduced release of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and stromal cell-derived factor 1-α. In addition, hASCs from elderly donors (>70 years) rarely differentiated into osteoblasts compared to hASCs derived from younger (<30 years) donors, as hASCs from the younger individuals revealed significantly higher calcium deposition in the Alizarin Red assay. Although the secretion of BMP-2 protein was similar among both groups, the expression of its receptor (BMPR1A) was lower in the elderly group. Thus, the author postulated that elderly hASCs might exhibit a weaker response to the BMP-2 protein due to the reduced expression of its receptor [48]. Together, emerging evidence suggests that age impairs the osteogenic potentials of hASCs.

3. Discussion

As summarized in Table 1, there is conflicting evidence regarding the effect of age on the osteogenic differentiation potential of hASCs. Some studies found no significant effect of donor age on the osteogenic potential of the cells, while other studies depicted a deteriorating effect. This inconsistency could be dependent on several limitations in the included studies. For example, the sample size could have been too small to generate statistically significant data. In just one study, hASCs were isolated from a large number of donors (n = 260 donors, aged 5–97 years) and demonstrated an age-dependent adverse effect on adipogenesis but not on osteogenesis or chondrogenesis [44]. As MSCs usually maintain a differentiation balance—if one differentiation lineage is favored, the other one is inhibited—the findings of the previously mentioned study partially support this paradigm [17].
Since there is no standard for age clustering, researchers grouped individuals in various ways. Often, the selected age range was not large enough to make a valid comparison. In other words, in many earlier observations, the age difference between young and elderly donors was small, which might have concealed a true age effect. Studies on hASCs isolated from donors with a narrower age range found no significant impact of age. For example, in a study by Horinouchi et al., the osteogenic potential of young individuals (>34 years) and adults (<54 years) remained unaffected by age in terms of bone mineralization and the expression levels of osteogenic genes (RUNX2 and CEBPA) [47]. In contrast, Park reported age-related alterations in bone mineralization and BMP-2 gene expression in hASCs from two groups of donors with a wider age range (<30 years vs. >70 years) [48]. Similarly, two studies included infants (<1 year) or children (6–12 years) and demonstrated that hASCs from infants and children have higher osteogenic potentials in comparison to hASCs from elderly people (>55 years) [38,43].
Notably, even though this review focuses on hASCs, some in vivo mouse models also reported a similar age-dependent effect when comparing ASCs isolated from mice with large age differences. For example, age-related alterations in ASC proliferation and differentiation were reported by Li and Doshida et al. in the same species but with distinct age groups, i.e., 1-month-old vs. 20-month-old, and 6-month-old vs. 29-month-old, respectively [50,51,52]. However, Shi et al. observed no significant effect of age on the differentiation potential of ASCs from 6-days-old and 60-days-old mice.
Thus, age-related changes in the osteogenic potential of hASCs might be visible when hASCs from very young and very old donors with distinct age differences are compared. As younger individuals are less likely to undergo surgery, hASCs from young donors are significantly harder to recruit for experimental studies. This might be the reason why previous studies did not investigate hASCs from distinct age groups. For the same reason, hASCs were obtained predominantly from females rather than males because females are more likely to undergo plastic surgery [53]. Interestingly, out of the six studies that recruited female donors only, three studies considered age range related to the perimenopause (40–50 years) and revealed that hASCs obtained from female individuals in their early 40s exhibited increased lipid accumulation and decreased potential to differentiate into osteogenic lineage compared to hASCs from younger (<30 years) and older (>55 years) women [35,40,47,54]. These authors postulate that menopause-related changes in estrogen levels could explain this transient effect of age on hASC function. It is well known that a declined estrogen level is associated with low-grade inflammation that triggers fat accumulation and activates osteoclasts to degrade bone tissue [55]. In conclusion, gender and menopausal status should be considered when grouping donors based on age, and future studies should further explore the effects of hormonal changes and osteoporosis on ASC properties.
Some authors reported high intragroup variability in hASC characterization and differentiation, which could conceal age-dependent effects This apparent high donor-to-donor variability could be attributed to other demographic and lifestyle factors, e.g., general health status, medical and disease history, body mass index, or epigenetic patterns related to the environment; donor habits may also influence experimental outcomes, as reviewed by Prieto González in 2019 [56]. These donor characteristics have been disregarded in the literature, and in many cases, BMI was used as the sole parameter to describe the obesity status of individuals [10,35,36,37,41,43,44,47]. Increased BMI as a marker of obesity is associated with a decreased osteogenic potential of hASCs [57]. However, the role of BMI in identifying people with obesity is controversial as it cannot distinguish fat from muscle or bone mass. Therefore, a more useful indicator of obesity should be used when defining non-obese donors of ASCs.
Studies evaluating the effect of age on bone tissue engineering used hASCs from diverse anatomical sites, including the abdomen, the epididymis, and the eyelid. Surgical methods of fat harvesting also varied between the presented studies. Differences in the anatomical origin of adipose tissue and surgical procedures may be the underlying confounder since hASCs from different donor sites and methods of extraction exhibit distinct biological properties [58]. For instance, Requicha et al. assessed the expression profile of osteogenic genes (COLIA1, RUNX2, and Osteocalcin) of hASCs from the canine subcutaneous and omental origin by RT-PCR analysis. While RUNX2 expression did not differ between the two fat depots, COLIA1 had significantly higher expression in subcutaneous hASCs, whereas osteocalcin displayed an inverse expression pattern [59].
Apart from donor-related factors, the proliferation as well as differentiation potential of hASCs are also influenced by long-term passage, cryopreservation, and culture conditions (Figure 3), as these parameters varied in previous reports [56,60]. Often, osteogenic induction was performed on cryopreserved cells, after passages 1 to 5 by using osteogenic induction media with different compositions. Furthermore, previous studies selected different endpoints as the marker of osteogenic differentiation with various readout methods. Growth factors and serum supplementation also greatly differ between laboratories. These experimental variations may influence hASC stemness, proliferation, and differentiation [56].
As mentioned before, an accurate definition of ASCs remains an open issue. Among the 15 included studies, 8 studies characterized ASCs based on 2006 ISCT criteria of antigen expression profile for MSCs (Table 2), while 7 studies characterized ASCs by plastic adherence property and tri-lineage differentiation capacity. These characteristics are common for all MSCs and therefore a distinction between ASCs and other MSCs was not apparent. None of the studies included specific markers of ASCs in SVF (CD31−, CD45−, CD235a−, and CD34+) and in culture (CD36+ and CD106−) jointly proposed by the IFATS and ISCT in 2013. Thus, a lack of a uniform method of characterization of ASCs could contribute to conflicting results in previous studies.

4. Conclusions

The effect of age on the osteogenic differentiation potential of hASCs has been highly debated in the literature, and hitherto, poor agreement has been achieved in previous studies. Factors that might contribute to a disagreement in previous research include experimental variables such as small sample size, the lack of standard age grouping, differences in protocols for osteogenic differentiation and readout methods, as well as donor-related factors, for instance, hormonal status, underlying disease conditions, and metabolic status of hASC donors. Apart from the effect of age, future studies should also consider the intrinsic and extrinsic factors that may influence the osteogenic potential of hASCs. Attempts should be made to minimize heterogeneity through the purification of ASCs based on unique cell surface markers.

Author Contributions

M.A.S. conceptualized, designed, and wrote the manuscript L.F.L., V.G.J.G., T.R., R.G. and J.P.B. edited and finalized the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

Supported by a grant from the Interdisciplinary Centre for Clinical Research within the faculty of Medicine at the RWTH Aachen University (project no. OC1-10).

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Pfeiffenberger, M.; Damerau, A.; Lang, A.; Buttgereit, F.; Hoff, P.; Gaber, T. Fracture Healing Research-Shift towards In Vitro Modeling? Biomedicines 2021, 9, 748. [Google Scholar] [CrossRef]
  2. Mende, W.; Götzl, R.; Kubo, Y.; Pufe, T.; Ruhl, T.; Beier, J.P. The Role of Adipose Stem Cells in Bone Regeneration and Bone Tissue Engineering. Cells 2021, 10, 975. [Google Scholar] [CrossRef]
  3. Bostrom, M.P. Expression of bone morphogenetic proteins in fracture healing. Clin. Orthop. Relat. Res. 1998, 355, S116–S123. [Google Scholar] [CrossRef]
  4. Cho, T.J.; Gerstenfeld, L.C.; Einhorn, T.A. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J. Bone Miner. Res. 2002, 17, 513–520. [Google Scholar] [CrossRef]
  5. Carter, D.R.; Beaupr, G.S.; Giori, N.J.; Helms, J.A. Mechanobiology of skeletal regeneration. Clin. Orthop. Relat. Res. 1998, 355, S41–S55. [Google Scholar] [CrossRef]
  6. Ghimire, S.; Miramini, S.; Edwards, G.; Rotne, R.; Xu, J.; Ebeling, P.; Zhang, L. The investigation of bone fracture healing under intramembranous and endochondral ossification. Bone Rep. 2021, 14, 100740. [Google Scholar] [CrossRef]
  7. Roberts, T.T.; Rosenbaum, A.J. Bone grafts, bone substitutes and orthobiologics: The bridge between basic science and clinical advancements in fracture healing. Organogenesis 2012, 8, 114–124. [Google Scholar] [CrossRef]
  8. Henkel, J.; Woodruff, M.; Epari, D.; Steck, R.; Glatt, V.; Dickinson, I.C.; Choong, P.; Schuetz, M.A.; Hutmacher, D.W. Bone Regeneration Based on Tissue Engineering Conceptions—A 21st Century Perspective. Bone Res. 2013, 1, 216–248. [Google Scholar] [CrossRef]
  9. Sui, B.; Hu, C.; Zheng, C.; Jin, Y. Microenvironmental Views on Mesenchymal Stem Cell Differentiation in Aging. J. Dent. Res. 2016, 95, 1333–1340. [Google Scholar] [CrossRef]
  10. Alt, E.U.; Senst, C.; Murthy, S.N.; Slakey, D.P.; Dupin, C.L.; Chaffin, A.E.; Kadowitz, P.J.; Izadpanah, R. Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res. 2012, 8, 215–225. [Google Scholar] [CrossRef]
  11. Rosenbaum, A.J.; Grande, D.A.; Dines, J.S. The use of mesenchymal stem cells in tissue engineering: A global assessment. Organogenesis 2008, 4, 23–27. [Google Scholar] [CrossRef]
  12. Oryan, A.; Kamali, A.; Moshiri, A.; Baghaban Eslaminejad, M. Role of Mesenchymal Stem Cells in Bone Regenerative Medicine: What Is the Evidence? Cells Tissues Organs 2017, 204, 59–83. [Google Scholar] [CrossRef]
  13. Sethe, S.; Scutt, A.; Stolzing, A. Aging of mesenchymal stem cells. Ageing Res. Rev. 2006, 5, 91–116. [Google Scholar] [CrossRef]
  14. Bellantuono, I.; Aldahmash, A.; Kassem, M. Aging of marrow stromal (skeletal) stem cells and their contribution to age-related bone loss. Biochim. Biophys. Acta 2009, 1792, 364–370. [Google Scholar] [CrossRef]
  15. Asumda, F.Z. Age-associated changes in the ecological niche: Implications for mesenchymal stem cell aging. Stem Cell Res. Ther. 2013, 4, 47. [Google Scholar] [CrossRef]
  16. Baker, N.; Boyette, L.B.; Tuan, R.S. Characterization of bone marrow-derived mesenchymal stem cells in aging. Bone 2015, 70, 37–47. [Google Scholar] [CrossRef]
  17. Infante, A.; Rodriguez, C.I. Osteogenesis and aging: Lessons from mesenchymal stem cells. Stem Cell Res. Ther. 2018, 9, 244. [Google Scholar] [CrossRef]
  18. Prall, W.C.; Saller, M.M.; Scheumaier, A.; Tucholski, T.; Taha, S.; Böcker, W.; Polzer, H. Proliferative and osteogenic differentiation capacity of mesenchymal stromal cells: Influence of harvesting site and donor age. Injury 2018, 49, 1504–1512. [Google Scholar] [CrossRef]
  19. Majors, A.K.; Boehm, C.A.; Nitto, H.; Midura, R.J.; Muschler, G.F. Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation. J. Orthop. Res. 1997, 15, 546–557. [Google Scholar] [CrossRef]
  20. Stolzing, A.; Jones, E.; McGonagle, D.; Scutt, A. Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies. Mech. Ageing Dev. 2008, 129, 163–173. [Google Scholar] [CrossRef]
  21. Stenderup, K.; Justesen, J.; Clausen, C.; Kassem, M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003, 33, 919–926. [Google Scholar] [CrossRef]
  22. Zhou, S.; Greenberger, J.S.; Epperly, M.W.; Goff, J.P.; Adler, C.; LeBoff, M.S.; Glowacki, J. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008, 7, 335–343. [Google Scholar] [CrossRef]
  23. Alonso-Goulart, V.; Ferreira, L.B.; Duarte, C.A.; de Lima, I.L.; Ferreira, E.R.; de Oliveira, B.C.; Vargas, L.N.; de Moraes, D.D.; Silva, I.B.B.; Faria, R.d.O.; et al. Mesenchymal stem cells from human adipose tissue and bone repair: A literature review. Biotechnol. Res. Innov. 2018, 2, 74–80. [Google Scholar] [CrossRef]
  24. Meyer, J.; Salamon, A.; Herzmann, N.; Adam, S.; Kleine, H.-D.; Matthiesen, I.; Ueberreiter, K.; Peters, K. Isolation and differentiation potential of human mesenchymal stem cells from adipose tissue harvested by water jet-assisted liposuction. Aesthet. Surg. J. 2015, 35, 1030–1039. [Google Scholar] [CrossRef]
  25. Al-Ghadban, S.; Artiles, M.; Bunnell, B.A. Adipose Stem Cells in Regenerative Medicine: Looking Forward. Front. Bioeng. Biotechnol. 2022, 9, 837464. [Google Scholar] [CrossRef]
  26. Diri, D.; Alasaad, H.; Muhammed, H.; Ibrahim, J. Case report: Adipose-derived mesenchymal stem cells combined with core decompression in the treatment of early-stage avascular necrosis of the femoral head. Int. J. Surg. Case Rep. 2023, 102, 107861. [Google Scholar]
  27. Li, C.; Mills, Z.; Zheng, Z. Novel cell sources for bone regeneration. MedComm 2021, 2, 145–174. [Google Scholar] [CrossRef]
  28. Bourin, P.; Bunnell, B.A.; Casteilla, L.; Dominici, M.; Katz, A.J.; March, K.L.; Redl, H.; Rubin, J.P.; Yoshimura, K.; Gimble, J.M. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy 2013, 15, 641–648. [Google Scholar]
  29. Setiawan, A.M.; Kamarudin, T.A.; Abd Ghafar, N. The role of BMP4 in adipose-derived stem cell differentiation: A minireview. Front. Cell Dev. Biol. 2022, 10, 1045103. [Google Scholar] [CrossRef]
  30. Li, X.; Yao, J.; Wu, L.; Jing, W.; Tang, W.; Lin, Y.; Tian, W.; Liu, L. Osteogenic induction of adipose-derived stromal cells: Not a requirement for bone formation in vivo. Artif. Organs 2010, 34, 46–54. [Google Scholar] [CrossRef]
  31. Yoshida, Y.; Matsubara, H.; Fang, X.; Hayashi, K.; Nomura, I.; Ugaji, S.; Hamada, T.; Tsuchiya, H. Adipose-derived stem cell sheets accelerate bone healing in rat femoral defects. PLoS ONE 2019, 14, e0214488. [Google Scholar] [CrossRef] [PubMed]
  32. Dufrane, D. Impact of Age on Human Adipose Stem Cells for Bone Tissue Engineering. Cell Transpl. 2017, 26, 1496–1504. [Google Scholar] [CrossRef]
  33. Varghese, J.; Griffin, M.; Mosahebi, A.; Butler, P. Systematic review of patient factors affecting adipose stem cell viability and function: Implications for regenerative therapy. Stem Cell Res. Ther. 2017, 8, 45. [Google Scholar] [CrossRef]
  34. Holtze, S.; Gorshkova, E.; Braude, S.; Cellerino, A.; Dammann, P.; Hildebrandt, T.B.; Hoeflich, A.; Hoffmann, S.; Koch, P.; Terzibasi Tozzini, E.; et al. Alternative Animal Models of Aging Research. Front. Mol. Biosci. 2021, 8, 660959. [Google Scholar] [CrossRef] [PubMed]
  35. Zhu, M.; Kohan, E.; Bradley, J.; Hedrick, M.; Benhaim, P.; Zuk, P. The effect of age on osteogenic, adipogenic and proliferative potential of female adipose-derived stem cells. J. Tissue Eng. Regen. Med. 2009, 3, 290–301. [Google Scholar] [CrossRef]
  36. Girolamo, L.; Lopa, S.; Arrigoni, E.; Sartori, M.; Preis, F.W.B.; Brini, A. Human adipose-derived stem cells isolated from young and elderly women: Their differentiation potential and scaffold interaction during in vitro osteoblastic differentiation. Cytotherapy 2009, 11, 793–803. [Google Scholar] [CrossRef]
  37. Chen, H.; Lee, M.; Chen, C.; Chuang, S.; Chang, L.; Ho, M.; Hung, S.; Fu, Y.; Wang, Y.; Wang, H.; et al. Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J. Cell. Mol. Med. 2012, 16, 582–592. [Google Scholar] [CrossRef]
  38. Wu, W.; Niklason, L.; Steinbacher, D.M. The effect of age on human adipose-derived stem cells. Plast. Reconstr. Surg. 2013, 131, 27–37. [Google Scholar] [CrossRef]
  39. Choudhery, M.S.; Badowski, M.; Muise, A.; Pierce, J.; Harris, D.T. Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation. J. Transl. Med. 2014, 12, 8. [Google Scholar] [CrossRef]
  40. Bodle, J.C.; Teeter, S.D.; Hluck, B.H.; Hardin, J.W.; Bernacki, S.H.; Loboa, E.G. Age-Related Effects on the Potency of Human Adipose-Derived Stem Cells: Creation and Evaluation of Superlots and Implications for Musculoskeletal Tissue Engineering Applications. Tissue Eng. Part C Methods 2014, 20, 972–983. [Google Scholar] [CrossRef]
  41. Ye, X.; Liao, C.; Liu, G.; Xu, Y.; Tan, J.; Song, Z. Age-Related Changes in the Regenerative Potential of Adipose-Derived Stem Cells Isolated from the Prominent Fat Pads in Human Lower Eyelids. PLoS ONE 2016, 11, e0166590. [Google Scholar] [CrossRef]
  42. Marędziak, M.; Marycz, K.; Tomaszewski, K.A.; Kornicka, K.; Henry, B.M. The Influence of Aging on the Regenerative Potential of Human Adipose Derived Mesenchymal Stem Cells. Stem Cells Int. 2016, 2016, 2152435. [Google Scholar] [CrossRef]
  43. Liu, M.; Lei, H.; Dong, P.; Fu, X.; Yang, Z.; Yang, Y.; Ma, J.; Liu, X.; Cao, Y.; Xiao, R. Adipose-Derived Mesenchymal Stem Cells from the Elderly Exhibit Decreased Migration and Differentiation Abilities with Senescent Properties. Cell Transpl. 2017, 26, 1505–1519. [Google Scholar] [CrossRef]
  44. Kawagishi-Hotta, M.; Hasegawa, S.; Igarashi, T.; Yamada, T.; Takahashi, M.; Numata, S.; Kobayashi, T.; Iwata, Y.; Arima, M.; Yamamoto, N.; et al. Enhancement of individual differences in proliferation and differentiation potentials of aged human adipose-derived stem cells. Regen. Ther. 2017, 6, 29–40. [Google Scholar] [CrossRef] [PubMed]
  45. Nordberg, R.C.; Zhang, J.; Griffith, E.H.; Frank, M.W.; Starly, B.; Loboa, E.G. Electrical Cell-Substrate Impedance Spectroscopy Can Monitor Age-Grouped Human Adipose Stem Cell Variability During Osteogenic Differentiation. Stem Cells Transl. Med. 2017, 6, 502–511. [Google Scholar] [CrossRef]
  46. Zhang, M.; Wang, Z.; Zhao, Y.; Zhang, L.; Xu, L.; Cao, L.; He, W. The Effect of Age on the Regenerative Potential of Human Eyelid Adipose-Derived Stem Cells. Stem Cells Int. 2018, 2018, 5654917. [Google Scholar] [CrossRef] [PubMed]
  47. Horinouchi, C.D.; Barisón, M.J.; Robert, A.W.; Kuligovski, C.; Aguiar, A.M.; Dallagiovanna, B. Influence of donor age on the differentiation and division capacity of human adipose-derived stem cells. World J. Stem Cells 2020, 12, 1640–1651. [Google Scholar] [CrossRef] [PubMed]
  48. Park, J.S.; Park, G.; Hong, H.S. Age affects the paracrine activity and differentiation potential of human adipose-derived stem cells. Mol. Med. Rep. 2021, 23, 160. [Google Scholar] [CrossRef] [PubMed]
  49. Kornicka, K.; Marycz, K.; Tomaszewski, K.A.; Marędziak, M.; Śmieszek, A. The Effect of Age on Osteogenic and Adipogenic Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) and the Impact of Stress Factors in the Course of the Differentiation Process. Oxidat. Med. Cell. Longev. 2015, 2015, 309169. [Google Scholar] [CrossRef]
  50. Li, K.; Shi, G.; Lei, X.; Huang, Y.; Li, X.; Bai, L.; Qin, C. Age-related alteration in characteristics, function, and transcription features of ADSCs. Stem Cell Res. Ther. 2021, 12, 473. [Google Scholar] [CrossRef]
  51. Doshida, Y.; Sano, H.; Iwabuchi, S.; Aigaki, T.; Yoshida, M.; Hashimoto, S.; Ishigami, A. Age-associated changes in the transcriptomes of non-cultured adipose-derived stem cells from young and old mice assessed via single-cell transcriptome analysis. PLoS ONE 2020, 15, e0242171. [Google Scholar] [CrossRef] [PubMed]
  52. Shi, Y.-Y.; Nacamuli, R.P.; Salim, A.; Longaker, M.T. The osteogenic potential of adipose-derived mesenchymal cells is maintained with aging. Plast. Reconstr. Surg. 2005, 116, 1686–1696. [Google Scholar] [CrossRef] [PubMed]
  53. Alotaibi, A.S. Demographic and Cultural Differences in the Acceptance and Pursuit of Cosmetic Surgery: A Systematic Literature Review. Plast. Reconstr. Surg. Glob. Open 2021, 9, e3501. [Google Scholar] [CrossRef] [PubMed]
  54. Schipper, B.M.; Marra, K.G.; Zhang, W.B.; Donnenberg, A.D.; Rubin, J.P. Regional anatomic and age effects on cell function of human adipose-derived stem cells. Ann. Plast. Surg. 2008, 60, 538–544. [Google Scholar] [CrossRef] [PubMed]
  55. Park, J.S.; Piao, J.; Park, G.; Yoo, K.S.; Hong, H.S. Osteoporotic Conditions Influence the Activity of Adipose-Derived Stem Cells. Tissue Eng. Regen. Med. 2020, 17, 875–885. [Google Scholar] [CrossRef] [PubMed]
  56. Prieto González, E.A. Heterogeneity in Adipose Stem Cells. Adv. Exp. Med. Biol. 2019, 1123, 119–150. [Google Scholar] [PubMed]
  57. Frazier, T.P.; Gimble, J.M.; Devay, J.W.; Tucker, H.A.; Chiu, E.S.; Rowan, B.G. Body mass index affects proliferation and osteogenic differentiation of human subcutaneous adipose tissue-derived stem cells. BMC Cell Biol. 2013, 14, 34. [Google Scholar] [CrossRef] [PubMed]
  58. Prunet-Marcassus, B.; Cousin, B.; Caton, D.; André, M.; Pénicaud, L.; Casteilla, L. From heterogeneity to plasticity in adipose tissues: Site-specific differences. Exp. Cell Res. 2006, 312, 727–736. [Google Scholar] [CrossRef]
  59. Requicha, J.F.; Viegas, C.A.; Albuquerque, C.M.; Azevedo, J.M.; Reis, R.L.; Gomes, M.E. Effect of Anatomical Origin and Cell Passage Number on the Stemness and Osteogenic Differentiation Potential of Canine Adipose-Derived Stem Cells. Stem Cell Rev. Rep. 2012, 8, 1211–1222. [Google Scholar] [CrossRef]
  60. Bogdanova, A.; Berzins, U.; Nikulshin, S.; Skrastina, D.; Ezerta, A.; Legzdina, D.; Kozlovska, T. Characterization of human adipose-derived stem cells cultured in autologous serum after subsequent passaging and long term cryopreservation. J. Stem Cells 2014, 9, 135–148. [Google Scholar]
Cimb 46 00092 g001
Figure 1. Schematic representation of the natural bone repair process. Immune cells associated with hematoma are formed in the first phase. In the second phase, MSCs are recruited and differentiated into chondroblasts and osteoblasts that help the formation of soft cartilage callus. VEGFs promote vascularization in this phase. In the third phase, soft cartilage is replaced by hard bone facilitated by osteoblasts, osteoclasts, chondroclasts, and chondroblasts. The final step involves the continuous remodeling of newly formed bone. The figure was modified from Pfeiffenberger et al. [1], licensed under a Creative Common Attribution (CC BY) 4.0 Generic License, https://creativecommons.org/licenses/by/4.0/) (accessed on 24 November 2023). Created with BioRender.com (accessed on 24 November 2023).
Figure 1. Schematic representation of the natural bone repair process. Immune cells associated with hematoma are formed in the first phase. In the second phase, MSCs are recruited and differentiated into chondroblasts and osteoblasts that help the formation of soft cartilage callus. VEGFs promote vascularization in this phase. In the third phase, soft cartilage is replaced by hard bone facilitated by osteoblasts, osteoclasts, chondroclasts, and chondroblasts. The final step involves the continuous remodeling of newly formed bone. The figure was modified from Pfeiffenberger et al. [1], licensed under a Creative Common Attribution (CC BY) 4.0 Generic License, https://creativecommons.org/licenses/by/4.0/) (accessed on 24 November 2023). Created with BioRender.com (accessed on 24 November 2023).
Cimb 46 00092 g001
Cimb 46 00092 g002
Figure 2. Flowchart demonstrating the selection process in this review.
Figure 2. Flowchart demonstrating the selection process in this review.
Cimb 46 00092 g002
Cimb 46 00092 g003
Figure 3. The osteogenic potential of ASC is influenced by both donor-related and experimental factors. Created with BioRender.com (accessed on 24 November 2023).
Figure 3. The osteogenic potential of ASC is influenced by both donor-related and experimental factors. Created with BioRender.com (accessed on 24 November 2023).
Cimb 46 00092 g003
Table 1. Summary of studies included in this review.
Table 1. Summary of studies included in this review.
YearAimStudy DesignMethodsResultsConclusionsOther VariablesRef.
2009Effect of donor age on differentiation potential of ASCs.ASCs from females aged 20–58 years;
N = 27, n = 9, 7, 11.		ALP activity after 7 days
Ca2+ deposition by von Kossa after 4 weeks		↓ ALP Activity with age
↓ Ca2+ deposition with age		Osteogenic differentiation decreases with ageSC: female, non-obese
AO: u.s (liposuction)
Passage: 1
OI day: up to 28 days		[35]
2009In vitro differentiation potential of ASCs from young and elderly females.Young (<35) and older (>45) females
N = 26.		ALP activity Assay after 14 days
Ca2+ deposition by Alizarin Red assay after 21 days		↓ ALP activity with age
No significant difference in Ca2+ deposition		Donor age mildly affects the potential of ASCs for osteogenic differentiation in vitroSC: non-obese female, BMI < 30
AO: subcutaneous (lipo-asp.)
Passage: 1
OI day: 21 days		[36]
2012Age-associated changes in molecular characteristics of ASCs.ASCs from healthy young (<20), middle-aged (30–40), and elderly (>50) donors.
N = 40; n = 15, 17, 8.		Ca2+ deposition by Alizarin Red S
ALP activity assay
Osteogenic gene (BMP-6, COL2A, COL10A) expression by RT-PCR		↓ Ca2+ deposition
↓ ALP activity
↓ Expression of osteogenic genes		Aging processes significantly attenuate the osteogenic differentiation potential of ASCsSC: healthy male/female, BMI < 29
AO: abdominal
Passage: u.s
OI day: u.s		[10]
2012Effect of age on ASCs and bmMSCs from elderly patients with osteoporosis.ASCs from young (<36) and elderly (>67) individuals
N = 22, n = 14, 8.		Ca2+ deposition by Alizarin Red SNo significant difference in Ca2+ deposition The osteogenic differentiation of ASCs is not impacted by ageSC: male/female, osteoporotic, BMI < 26
AO: gluteal subcutaneous
Passage: 5
OI day: up to 14 days		[37]
Osteogenic genes (OCA, BMP2, RUNX2, and ALP) by RT-PCRNo significant difference in gene expression.
2012Effect of aging on senescence, osteogenic factors, and osteogenesis of ASCs.ASCs from infants (<1), adults (20–54), and elderly individuals (>55),
N = 13; n = 4, 6, 3.		Senescence (TL) by RT-PCR
RUNX2, osteocalcin by RT-PCR
ALP activity assay
Ca2+ deposition by Alizarin Red S		↑ Senescence with age
↓ Osteogenic gene expression compared to infant
↓ ALP activity and Ca2+ deposition compared to infant.		Biological properties are conserved during the adult to the elderly period (but not compared to infants)SC: male/female.
AO: abdominal (liposuction)
Passage: 1
OI day: up to 21 days		[38]
2014Impact of age on the quality of human adipose tissue-derived MSCs.ASCs of young (<30), adult (35–50), and elderly (>60) donors,
N = 29; n = 10, 8, 11.		Ca2+ deposition by von Kossa staining
Senescence by β-galactosidase Staining
Osteogenic genes (osteocalcin and ALP) by RT-PCR		↓ Ca2+ deposition with age
↑ Senescence with age
↓ Expression of osteocalcin and ALP with age.		Age negatively impacts stem cell osteogenic differentiationSC: male/female
AO: (liposuction)
Passage: 2–3
OI day: 21 days		[39]
2014Effect of age on osteogenesis of female ASCs: superlot approach.ASCs from female patients (24–81), superlot biobanking.
N = 14; n = 5, 4, 5.		Ca2+ deposition by Alizarin Red S↑ Ca2+ deposition with older (postmenopausal) female.Existence of a high degree of donor-to-donor variations which is independent of age SC: female
AO: u.s
Passage: 1
OI day: 14 days		[40]
2016Effects of donor age on the biological properties of human OASC.OASCs from young (20–38, normal) and old donors (50–67, fat pad in lower eyelid)
N = 20; n = 10, 10.		Ca2+ deposition by Alizarin Red S
Ca2+ deposition by Von Kossa staining		↓ Ca2+ deposition with ageThe benefit of autologous OASCs from elderly patients for osteogenic therapeutic purposes may be limitedSC: female, non-obese
AO: lower eyelid fat pad
Passage: 3
OI day: 14 days		[41]
2016Effect of age on the osteogenic potential of ASCs.ASCs from different age groups:
>20 y, >50 y, >60, >70
N = 32; n = 8.		Ca2+ deposition by Alizarin Red
ALP activity assay
Osteogenic markers (OPN, Col-I, OCL, and BMP-2) by PCR		↓ Ca2+ deposition with age
No significant difference in ALP activity
↓ Expression of osteogenic markers with age		Age negatively influences the osteogenic potential of ASCsSC: healthy male/female
AO: subcutaneous
Passage: 1
OI day: 21 days		[42]
2017Systematical analysis of the effects of age on the quantity and quality of ASCs.ASCs were isolated from children (6–12), young individuals (22–27), adults (60–73), and the elderly, N = 24; n = 10, 8, 6.Cellular senescence assay
Ca2+ deposition by Alizarin Red S
Osteogenic genes (RUNX2, ALP, OCN, and OPN) by RT-PCR		ASCs from elderly donors exhibit senescent properties.
ASCs from aged patients exhibit impaired osteogenic potential		While ASCs from different age populations are phenotypically similar, they present major differences at the functional levelSC: male/female BMI < 22
AO: chest subcutaneous
Passage: 3
OI day: up to 21 days		[43]
2017Effect of donor age on differentiation potential of ASCs.ASCs of 260 donors (ages 5–97 years)
N = 260.		Ca2+ deposition by Alizarin Red SThe osteogenic potential (marked by Ca2+ deposition) of ASCs does not correlate with donor ageThe chondrogenic and osteogenic potential of ASCs were not affected by ageSC: male/female, median BMI = 22.7
AO: subcutaneous
Passage: 5
OI day: 21 days		[44]
2017Cell–substrate impedance spectroscopy (ECIS) to track complex bioimpedance pattern of ASC osteogenesis.ASC superlot from young (24–36), middle-aged (48–55), and elderly (60–81) adults.ECIS measurement throughout the osteogenic differentiation phasesASCs from younger donors require a longer time to differentiate than ASCs from older donors.Donor age may temporally control the onset of osteogenesisSC: female
AO: u.s (liposuction)
Passage: u.s
CS: u.s
OI day: u.s		[45]
2018Effect of donor age on the regenerative potential of HEASCs.HEASCs from <20 y, >20 y, <45 y, >55 y
N = 13; n = 4, 5, 4.		Ca2+ deposition by Alizarin Red S
RUNX2 by RT-PCR		↓ Ca2+ deposition with age
No difference in gene expression.		Donor age has a negative influence on the osteogenic differentiation of HEASCsSC: healthy donor
AO: eyelid
Passage: 5
OI day: 21 days		[46]
2020Differentiation potential of ASCs isolated from the lipoaspirates of elderly and young donors.ASCs from young (<34) and old (>54) female donors, N = 18; n = 9, 9.Cell mineralization assay
RUNX2 by RT-PCR		No significant difference
No significant difference		Age does not significantly impact the osteogenesis of ASCsSC: female, BMI < 30;
AO: u.s (liposuction)
Passage: 4–7
OI day: up to 28 days		[47]
2021Association between age and ASC differentiation potential.ASCs from young (<30) and elderly (>70),
N = 8.		Ca2+ deposition by Alizarin Red S
BMP-2 by ELISA
BMP-2 receptor by WB		↓ Ca2+ deposition with age
No significant difference
↓ BMP-2 with age		Age may affect the cellular function and differentiation of ASCsSC: healthy male/female,
AO: u.s
Passage: 3–5
OI day: 20 days		[48]
Abbreviations: TL = telomere length; GF = growth factor, ns = not significant, rhBMP-2 = recombinant human bone morphogenic protein 2; HEASC = Human eyelid adipose stem cell, DM = diabetic mellitus; ECM = extracellular matrix, ECIS = cell–substrate impedance spectroscopy, OASC = orbital adipose-derived stem cell, GF = growth factor, OCA = osteocalcin, BMP = bone morphogenic protein, ALP = alkaline phosphatase, N = total number of participants/animal, n = sample size (number in each group), SC = sample characteristics, AO = anatomical origin, CS = centrifugal speed, OI = osteogenic induction, u.s = unspecified, Ns = not significant, ↑ = increasing/upregulated, ↓ = decreasing/downregulated.
Table 2. ASC characterization methods described in the included studies.
Table 2. ASC characterization methods described in the included studies.
MethodPositive MarkersNegative MarkersReferences
Flow CytometryCD44, CD90, CD105, CD146CD3, CD4, CD11b, CD34, CD45[10]
Flow CytometryCD44, CD73, CD90,CD105-[38]
Flow CytometryCD44, CD73, CD90, CD105CD3, CD14, CD19, CD34, CD45[39]
Flow CytometryCD73, CD90, CD105CD14, CD19, CD34, CD45[41]
Flow CytometryCD44, CD73, CD90, CD105CD34, CD45[42]
Flow CytometryCD44, CD73, CD90, CD105CD34, CD11b, CD19, CD45, HLA-DR[43]
RT-qPCRCD44, CD73, CD90, CD105, CD271, NANOG-[44]
Flow CytometryCD44, CD73, CD90, CD105CD31, CD34, CD45[46]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sattar, M.A.; Lingens, L.F.; Guillaume, V.G.J.; Goetzl, R.; Beier, J.P.; Ruhl, T. Association between Donor Age and Osteogenic Potential of Human Adipose Stem Cells in Bone Tissue Engineering. Curr. Issues Mol. Biol. 2024, 46, 1424-1436. https://doi.org/10.3390/cimb46020092

AMA Style

Sattar MA, Lingens LF, Guillaume VGJ, Goetzl R, Beier JP, Ruhl T. Association between Donor Age and Osteogenic Potential of Human Adipose Stem Cells in Bone Tissue Engineering. Current Issues in Molecular Biology. 2024; 46(2):1424-1436. https://doi.org/10.3390/cimb46020092

Chicago/Turabian Style

Sattar, Md Abdus, Lara F. Lingens, Vincent G. J. Guillaume, Rebekka Goetzl, Justus P. Beier, and Tim Ruhl. 2024. "Association between Donor Age and Osteogenic Potential of Human Adipose Stem Cells in Bone Tissue Engineering" Current Issues in Molecular Biology 46, no. 2: 1424-1436. https://doi.org/10.3390/cimb46020092

APA Style

Sattar, M. A., Lingens, L. F., Guillaume, V. G. J., Goetzl, R., Beier, J. P., & Ruhl, T. (2024). Association between Donor Age and Osteogenic Potential of Human Adipose Stem Cells in Bone Tissue Engineering. Current Issues in Molecular Biology, 46(2), 1424-1436. https://doi.org/10.3390/cimb46020092

Article Metrics

Back to TopTop